Free Trial

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Bolt Biotherapeutics logo
$5.77 +0.16 (+2.85%)
As of 03:58 PM Eastern

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Key Stats

Today's Range
$5.55
$5.87
50-Day Range
$5.59
$7.80
52-Week Range
$5.20
$15.60
Volume
23,736 shs
Average Volume
11,177 shs
Market Capitalization
$11.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00
Consensus Rating
Hold

Company Overview

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Bolt Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

BOLT MarketRank™: 

Bolt Biotherapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 422nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bolt Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bolt Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bolt Biotherapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bolt Biotherapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bolt Biotherapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bolt Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.83% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 6.98%, indicating that investor sentiment is decreasing significantly.
  • Percentage of Shares Shorted

    1.83% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 6.98%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bolt Biotherapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Bolt Biotherapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of Bolt Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bolt Biotherapeutics' insider trading history.
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
See More Headlines

BOLT Stock Analysis - Frequently Asked Questions

Bolt Biotherapeutics' stock was trading at $10.7020 on January 1st, 2025. Since then, BOLT shares have decreased by 46.1% and is now trading at $5.77.
View the best growth stocks for 2025 here
.

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings data on Monday, May, 12th. The company reported ($5.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($6.80) by $1.00. The company earned $1.22 million during the quarter, compared to analyst estimates of $0.77 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 94.51% and a negative net margin of 665.56%.

Bolt Biotherapeutics's stock reverse split on Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV).

Company Calendar

Last Earnings
5/12/2025
Today
6/30/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BOLT
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.00
High Stock Price Target
$80.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+788.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.12 million
Net Margins
-665.56%
Pretax Margin
-1,741.26%

Debt

Sales & Book Value

Annual Sales
$7.69 million
Price / Cash Flow
N/A
Book Value
$29.89 per share
Price / Book
0.19

Miscellaneous

Free Float
1,325,000
Market Cap
$10.80 million
Optionable
Not Optionable
Beta
0.92

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:BOLT) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners